Kite Pharma Inc (KITE) Position Lessened by DSAM Partners London Ltd
DSAM Partners London Ltd cut its holdings in Kite Pharma Inc (NASDAQ:KITE) by 96.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,864 shares of the biopharmaceutical company’s stock after selling 90,106 shares during the quarter. DSAM Partners London Ltd’s holdings in Kite Pharma were worth $515,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also bought and sold shares of KITE. Parametric Portfolio Associates LLC grew its stake in shares of Kite Pharma by 95.7% in the first quarter. Parametric Portfolio Associates LLC now owns 35,965 shares of the biopharmaceutical company’s stock worth $2,823,000 after purchasing an additional 17,588 shares during the last quarter. Wellington Management Group LLP bought a new stake in Kite Pharma during the 1st quarter valued at approximately $3,959,000. Teachers Advisors LLC boosted its position in Kite Pharma by 2.6% during the 1st quarter. Teachers Advisors LLC now owns 119,749 shares of the biopharmaceutical company’s stock valued at $9,399,000 after acquiring an additional 3,014 shares in the last quarter. Legal & General Group Plc boosted its position in Kite Pharma by 8.0% during the 1st quarter. Legal & General Group Plc now owns 14,578 shares of the biopharmaceutical company’s stock valued at $1,145,000 after acquiring an additional 1,080 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Kite Pharma by 16.1% during the 1st quarter. Vanguard Group Inc. now owns 3,661,547 shares of the biopharmaceutical company’s stock valued at $287,395,000 after acquiring an additional 507,289 shares in the last quarter. 87.72% of the stock is currently owned by institutional investors.
In related news, COO Cynthia M. Butitta sold 15,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $120.72, for a total transaction of $1,810,800.00. Following the completion of the transaction, the chief operating officer now owns 132,795 shares of the company’s stock, valued at $16,031,012.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Helen Susan Kim sold 79,949 shares of the firm’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $119.56, for a total transaction of $9,558,702.44. Following the transaction, the executive vice president now directly owns 98,613 shares of the company’s stock, valued at approximately $11,790,170.28. The disclosure for this sale can be found here. Insiders have sold 150,136 shares of company stock valued at $20,912,027 over the last quarter. Insiders own 14.00% of the company’s stock.
Kite Pharma (NASDAQ:KITE) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.97) by $0.03. Kite Pharma had a negative net margin of 1,092.54% and a negative return on equity of 59.15%. The business had revenue of $10.10 million during the quarter, compared to the consensus estimate of $9.59 million. During the same period in the previous year, the firm posted ($0.91) earnings per share. The business’s revenue for the quarter was up 110.4% compared to the same quarter last year.
Several research firms have weighed in on KITE. SunTrust Banks, Inc. cut Kite Pharma from a “buy” rating to a “hold” rating in a research report on Monday, August 28th. Wedbush raised Kite Pharma from an “underperform” rating to a “neutral” rating in a research report on Tuesday, August 29th. BTIG Research cut Kite Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, August 28th. Jefferies Group LLC reaffirmed a “buy” rating and set a $135.00 price objective (up from $121.00) on shares of Kite Pharma in a research report on Wednesday, August 9th. Finally, Canaccord Genuity set a $120.00 price objective on Kite Pharma and gave the company a “buy” rating in a research report on Wednesday, August 9th. Thirteen investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $94.68.
COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/11/03/kite-pharma-inc-kite-position-lessened-by-dsam-partners-london-ltd.html.
Kite Pharma Profile
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Receive News & Stock Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related stocks with our FREE daily email newsletter.